Chemoradiation with FOLFOX in Oesophageal Cancer
Author Information
Author(s): Conroy T, Viret F, François E, Seitz J F, Boige V, Ducreux M, Ychou M, Metges J P, Giovannini M, Yataghene Y, Peiffert D
Primary Institution: Department of Medical Oncology and Radiotherapy, EA 4003, Nancy-University and Centre Alexis Vautrin
Hypothesis
The study aims to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of FOLFOX combined with radiotherapy for oesophageal cancer.
Conclusion
The FOLFOX-4 regimen was reasonably well tolerated and effective in inoperable/metastatic oesophageal carcinoma and warrants additional investigation.
Supporting Evidence
- Maximum tolerated dose was oxaliplatin 100 mg/m2.
- Overall response rate was 48.5%, including 12% complete response.
- Response rate on primary tumour was 62.9%.
- Median survival was 9.5 months.
Takeaway
Doctors tested a new treatment for a type of cancer in the esophagus, and it helped many patients feel better and live longer.
Methodology
Patients received three courses of FOLFOX regimen and escalating doses of oxaliplatin with concurrent radiotherapy.
Limitations
The study included patients with inoperable or metastatic disease, which may limit generalizability.
Participant Demographics
{"age_mean":58.2,"age_range":"37-75","gender_distribution":{"male":26,"female":7},"performance_status":{"0":5,"1":27,"2":2},"stage_distribution":{"III":12,"IV":21}}
Statistical Information
Confidence Interval
95% CI: 30.8–66.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website